Going past the data for temozolomide

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 1113-1115

  Villano, J Lee ^a   Letarte, Nathalie ^b   Bressler, Linda R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adjuvant therapy; Brain tumor; Glioblastoma; Temozolomide

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; LENALIDOMIDE; TEMOZOLOMIDE;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; GLIOBLASTOMA; HUMANS; TREATMENT OUTCOME;

EID: 84859803684     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1796-4     Document Type: Note

References (23)

1. Stupp R, Hegi ME, Mason WP et al (2009) EVects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
2. Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197
3. Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372-1380
4. Vredenburgh JJ, Desjardins A, Reardon DA et al (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119-4124
5. Hau P, Koch D, Hundsberger T et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688-690 (Pubitemid 46667817)
6. Khasraw M, Bell D, Wheeler H (2009) Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci 16:854-855
7. Poelen J, Prick MJ, Jeuken JW et al (2009) Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma. Acta Neurol Belg 109:238-242
8. Stern JI, Apisarnthanarax S, Paleologos NA et al (2003) Temozolomide as long-term maintenance treatment for gliomas. Ann Neurol 54:S31-S32
9. Gilbert M, Wang M, Aldape K et al (2011) RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29:suppl; abstract 2006
10. National Cancer Institute (2011) Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma, In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00626990
11. National Cancer Institute (2011) Radiation therapy with or without temozolomide in treating patients with low-grade glioma, In: ClinicalTrials. gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials. gov/show/NCT00978458
12. National Cancer Institute (2011) Radiation therapy with or without temozolomide in treating patients with anaplastic glioma, In: ClinicalTrials. gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials. gov/show/NCT00626990
13. National Cancer Institute (2011) Radiation therapy or radiation therapy and temozolomide or temozolomide alone in treating patients with newly diagnosed anaplastic glioma, In: ClinicalTrials. gov. Bethesda (MD): National Library of Medicine (US). http:// clinicaltrials.gov/show/NCT00887146
14. Villano JL, Letarte N, Yu JM et al (2011) Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol [Epub ahead of print]
15. FDA 2007 Temozolomide (marketed as Temodar): Aplastic anemia. Drug safety newsletter 1:7
16. Chamberlain MC, Raizer J (2009) Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol 93:229-232
17. De Vita S, De Matteis S, Laurenti L et al (2005) Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 84:760-762 (Pubitemid 41447813)
18. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small- cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010 (Pubitemid 46606390)
19. Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755-5760
20. The Myeloma Beacon StaV (2011) Revlimid cancer controversy flares, URL: http://www.myelomabeacon.com/news/2011/02/05/ revlimid-lenalidomide-cancer- controversy-flares/
21. Tancini G, Bonadonna G, Valagussa P et al (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2-10 (Pubitemid 13066135)
22. Einhorn LH, Williams SD, Troner M et al (1981) The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 305:727-731 (Pubitemid 11062055)
23. O'Connell MJ, Laurie JA, Kahn M et al (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300 (Pubitemid 28041612)